MTOR and female reproductive organ cancer: Alternatively, screening for PIK3CA mutations with targeted use of mTOR inhibitors may be another useful strategy since patients with these mutations may be more responsive to PI3K/AKT/mTOR inhibitors than patients without these mutations in gynecologic cancers [3].